Evidence map›Paper›PMID 38855749›Full record

ArticleFrontiers in pharmacology2024

Natural compound Alternol exerts a broad anti-cancer spectrum and a superior therapeutic safety index

Chenchen He, Linlin Ma, Jeff Hirst, Fei Li, Hao Wu, Wang Liu, Jiang Zhao, Feng Xu, Andrew K Godwin, Xiangwei Wang and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chenchen HeDepartment of Radiation Oncology, The First Affiliated Hospital of Xi'An Jiaotong University, Xi'An, China.
Linlin MaDepartment of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.
Jeff HirstDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
Fei LiDepartment of Physiology, Shenyang Pharmaceutical University, Shenyang, China.
Hao WuDepartment of Physiology, Shenyang Pharmaceutical University, Shenyang, China.
Wang LiuDepartment of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.
Jiang ZhaoDepartment of Urology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Feng XuDepartment of Physiology, Shenyang Pharmaceutical University, Shenyang, China.
Andrew K GodwinDepartment of Radiation Oncology, The First Affiliated Hospital of Xi'An Jiaotong University, Xi'An, China.
Xiangwei WangDepartment of Urology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Benyi LiDepartment of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.

Funding

Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Diane E Mahoney · 2019 to 2026
$21.5M
NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

Introduction: Alternol is a natural compound isolated from the fermentation of a mutated fungus. We have demonstrated its potent anti-cancer effect Methods: We first tested its anti-cancer spectrum using the National Cancer Institute-60 (NCI-60) screening, a protein quantitation-based assay. CellTiter-Glo screening was utilized for ovarian cancer cell lines. Cell cycle distribution was analyzed using flow cytometry. Xenograft models in nude mice were used to assess anti-cancer effect. Healthy mice were tested for the acuate systemic toxicity. Results: Our results showed that Alternol exerted a potent anti-cancer effect on 50 (83%) cancer cell lines with a GI Conclusion: Taken together, Alternol has a broad anti-cancer spectrum with a safe therapeutic index

Indexed as

Alternolanti-cancer drugnatural compoundovarian cancerprostate cancer

Identifiers

PMID38855749
PMCPMC11157072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.